Corvus Pharmaceuticals Book Value Per Share Growth & History (CRVS)
Corvus Pharmaceuticals's book value per share was $0.82 for fiscal 2025.
View full Corvus Pharmaceuticals company overviewCorvus Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.82 | $0.34 | +70.83% |
| 2024 | 2024-12-31 | $0.48 | -$0.31 | −39.20% |
| 2023 | 2023-12-31 | $0.79 | -$0.42 | −34.56% |
| 2022 | 2022-12-31 | $1.21 | -$0.88 | −42.25% |
| 2021 | 2021-12-31 | $2.09 | -$0.46 | −17.92% |
| 2020 | 2020-12-31 | $2.54 | -$0.00 | −0.04% |
| 2019 | 2019-12-31 | $2.54 | -$1.22 | −32.39% |
| 2018 | 2018-12-31 | $3.76 | -$0.27 | −6.68% |
| 2017 | 2017-12-31 | $4.03 | -$2.32 | −36.48% |
| 2016 | 2016-12-31 | $6.35 | $28.07 | — |
| 2015 | 2015-12-31 | -$21.72 | -$20.79 | — |
| 2014 | 2014-12-31 | -$0.93 | — | — |
Corvus Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.68 | $1.60 | +148.78% |
| Q1 2026 | 2026-03-31 | $2.86 | $2.14 | +295.56% |
| Q4 2025 | 2025-12-31 | $0.82 | $0.34 | +70.83% |
| Q3 2025 | 2025-09-30 | $0.96 | $0.76 | +384.63% |
| Q2 2025 | 2025-06-30 | $1.08 | $0.26 | +31.47% |
| Q1 2025 | 2025-03-31 | $0.72 | $0.04 | +6.35% |
| Q4 2024 | 2024-12-31 | $0.48 | -$0.31 | −39.20% |
| Q3 2024 | 2024-09-30 | $0.20 | -$0.70 | −78.04% |
| Q2 2024 | 2024-06-30 | $0.82 | -$0.19 | −19.07% |
| Q1 2024 | 2024-03-31 | $0.68 | -$0.37 | −35.16% |
| Q4 2023 | 2023-12-31 | $0.79 | -$0.42 | −34.56% |
| Q3 2023 | 2023-09-30 | $0.90 | -$0.49 | −35.00% |
| Q2 2023 | 2023-06-30 | $1.01 | -$0.71 | −41.40% |
| Q1 2023 | 2023-03-31 | $1.05 | -$0.88 | −45.55% |
| Q4 2022 | 2022-12-31 | $1.21 | -$0.88 | −42.25% |
| Q3 2022 | 2022-09-30 | $1.39 | -$0.87 | −38.49% |
| Q2 2022 | 2022-06-30 | $1.73 | -$0.55 | −24.02% |
| Q1 2022 | 2022-03-31 | $1.93 | -$0.54 | −21.77% |
| Q4 2021 | 2021-12-31 | $2.09 | -$0.46 | −17.92% |
| Q3 2021 | 2021-09-30 | $2.26 | $0.75 | +49.67% |
| Q2 2021 | 2021-06-30 | $2.27 | $0.46 | +25.31% |
| Q1 2021 | 2021-03-31 | $2.46 | $0.32 | +14.72% |
| Q4 2020 | 2020-12-31 | $2.54 | -$0.00 | −0.04% |
| Q3 2020 | 2020-09-30 | $1.51 | -$1.23 | −44.81% |
| Q2 2020 | 2020-06-30 | $1.81 | -$1.24 | −40.64% |
| Q1 2020 | 2020-03-31 | $2.15 | -$1.29 | −37.45% |
| Q4 2019 | 2019-12-31 | $2.54 | -$1.22 | −32.39% |
| Q3 2019 | 2019-09-30 | $2.73 | -$1.32 | −32.62% |
| Q2 2019 | 2019-06-30 | $3.05 | -$1.31 | −29.99% |
| Q1 2019 | 2019-03-31 | $3.43 | -$1.27 | −26.98% |
| Q4 2018 | 2018-12-31 | $3.76 | -$0.27 | −6.68% |
| Q3 2018 | 2018-09-30 | $4.06 | -$0.42 | −9.32% |
| Q2 2018 | 2018-06-30 | $4.36 | -$0.64 | −12.83% |
| Q1 2018 | 2018-03-31 | $4.70 | -$0.95 | −16.74% |
| Q4 2017 | 2017-12-31 | $4.03 | -$2.32 | −36.48% |
| Q3 2017 | 2017-09-30 | $4.48 | -$2.36 | −34.51% |
| Q2 2017 | 2017-06-30 | $5.01 | -$2.26 | −31.13% |
| Q1 2017 | 2017-03-31 | $5.65 | -$1.83 | −24.45% |
| Q4 2016 | 2016-12-31 | $6.35 | $28.07 | — |
| Q3 2016 | 2016-09-30 | $6.83 | — | — |
| Q2 2016 | 2016-06-30 | $7.27 | — | — |
| Q1 2016 | 2016-03-31 | $7.48 | — | — |
| Q4 2015 | 2015-12-31 | -$21.72 | — | — |
Corvus Pharmaceuticals book value per share trends
Over the last five fiscal years, Corvus Pharmaceuticals's book value per share decreased from $2.54 to $0.82, a change of -$1.72. The latest reported quarter, Q2 2026, shows $2.68.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corvus Pharmaceuticals source filings ↗